Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Beone Medicines Ltd (ONC)

Beone Medicines Ltd (ONC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,820,416
  • Shares Outstanding, K 118,537
  • Annual Sales, $ 3,810 M
  • Annual Income, $ -644,790 K
  • EBIT $ 183 M
  • EBITDA $ 354 M
  • 60-Month Beta 0.45
  • Price/Sales 9.98
  • Price/Cash Flow N/A
  • Price/Book 8.52

Options Overview Details

View History
  • Implied Volatility 45.53% (+2.98%)
  • Historical Volatility 45.40%
  • IV Percentile 55%
  • IV Rank 23.27%
  • IV High 67.80% on 04/14/25
  • IV Low 38.77% on 03/26/25
  • Expected Move (DTE 4) 15.10 (4.73%)
  • Put/Call Vol Ratio 0.35
  • Today's Volume 27
  • Volume Avg (30-Day) 142
  • Put/Call OI Ratio 1.58
  • Today's Open Interest 3,994
  • Open Int (30-Day) 4,192
  • Expected Range 303.96 to 334.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.71
  • Number of Estimates 2
  • High Estimate 1.81
  • Low Estimate 1.60
  • Prior Year -1.43
  • Growth Rate Est. (year over year) +219.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
310.11 +2.89%
on 12/05/25
385.22 -17.17%
on 11/17/25
-58.41 (-15.47%)
since 11/12/25
3-Month
306.00 +4.27%
on 10/23/25
385.22 -17.17%
on 11/17/25
-5.28 (-1.63%)
since 09/12/25
52-Week
170.99 +86.60%
on 12/19/24
385.22 -17.17%
on 11/17/25
+138.79 (+76.99%)
since 12/12/24

Most Recent Stories

More News
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data...

ONC : 319.06 (-0.55%)
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated...

ONC : 319.06 (-0.55%)
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancer Sonrotoclax previously received...

ONC : 319.06 (-0.55%)
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

BRUKINSA now demonstrates best-in-class sustained efficacy and long-term benefit with a favorable safety profile over more than six years of follow-up data in treatment-naïve and R/R CLL ...

ONC : 319.06 (-0.55%)
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

ZIIHERA plus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapy ...

ONC : 319.06 (-0.55%)
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates

Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024 Global BRUKINSA ® (zanubrutinib)...

ONC : 319.06 (-0.55%)
BeOne Medicines to Present at Upcoming Investor Conferences

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in fireside chats at two upcoming investor conferences: ...

ONC : 319.06 (-0.55%)
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2025 financial results on Thursday, November 6, 2025 before the financial markets...

ONC : 319.06 (-0.55%)
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

New data from two pivotal TEVIMBRA studies – RATIONALE-307 and -312 – reinforce the PD-1 inhibitor’s proven clinical benefit in both NSCLC and ES-SCLC Early data...

ONC : 319.06 (-0.55%)
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory mantle cell lymphoma (MCL) BeOne...

ONC : 319.06 (-0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

BeOne Medicines is an oncology company which involved in discovering and developing treatments to cancer patients. BeOne Medicines, formerly known as BeiGene Ltd., is based in SAN CARLOS, Calif.

See More

Key Turning Points

3rd Resistance Point 326.17
2nd Resistance Point 324.36
1st Resistance Point 321.71
Last Price 319.06
1st Support Level 317.25
2nd Support Level 315.44
3rd Support Level 312.79

See More

52-Week High 385.22
Last Price 319.06
Fibonacci 61.8% 303.38
Fibonacci 50% 278.11
Fibonacci 38.2% 252.83
52-Week Low 170.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar